tirzepatide in type 1 diabetes Shows Substantial Weight Loss for Patients With Tirzepatide Leads to Significant Weight
Description
*Percent Daily Values (DV) are based on a 2000 calorie diet
Long-term management strategies are therefore required that are effective at controlling dysglycaemia, well tolerated and, ideally, offer additional cardiovascular disease (CVD) risk-reduction benefits
Custom generation of recombinant monoclonal anti-idiotypic antibodies to support biotherapeutic drug development
Quality & Product Standards
In participants with obesity and chronic kidney disease without diabetes, once-weekly administration of semaglutide 2.4mg led to a reduction in albuminuria, body weight and systolic blood pressure compared with placebo, with no changes to creatinine or cystatin-C estimated glomerular filtration rate or measured glomerular filtration rate during the 24-week follow-up period.
Causes 1
